MedTrace Logo

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

NCT06399315 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2025-12-09

No results posted yet for this study

Summary

This is a clinical study aiming to assess pharmacokinetics and biomarker evidence of ZE46-0134 efficacy in Healthy Volunteers after single and multiple daily doses of the study drug

Conditions

Interventions

DRUG

ZE46-0134 or placebo

The patients will receive ZE46-0134 or placebo

DRUG

Rabeprazole, 20mg oral

Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered

DRUG

Itraconazole (200 mg)

Itraconazole 200 mg BID

Sponsors & Collaborators

  • Lomond Therapeutics Holdings, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-28
Primary Completion
2025-06-30
Completion
2025-08-26

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06399315 on ClinicalTrials.gov